Cargando…
Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181111/ https://www.ncbi.nlm.nih.gov/pubmed/30323656 http://dx.doi.org/10.2147/JPR.S152216 |
_version_ | 1783362344548564992 |
---|---|
author | Oswald, Jessica C Schuster, Nathaniel M |
author_facet | Oswald, Jessica C Schuster, Nathaniel M |
author_sort | Oswald, Jessica C |
collection | PubMed |
description | Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the vasoconstriction associated with triptans limit their use in patients with pre-existing cardiovascular risk factors. Preferential 5-HT(1F) agonists have shown promising results in in vitro and early proof-of-concept trials. Lasmiditan, a highly selective 5-HT(1F) agonist, has completed two Phase III randomized, double blind, placebo-controlled clinical trials, with a third – a long-term, open-label safety study – still underway. Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors. |
format | Online Article Text |
id | pubmed-6181111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61811112018-10-15 Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice Oswald, Jessica C Schuster, Nathaniel M J Pain Res Review Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the vasoconstriction associated with triptans limit their use in patients with pre-existing cardiovascular risk factors. Preferential 5-HT(1F) agonists have shown promising results in in vitro and early proof-of-concept trials. Lasmiditan, a highly selective 5-HT(1F) agonist, has completed two Phase III randomized, double blind, placebo-controlled clinical trials, with a third – a long-term, open-label safety study – still underway. Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors. Dove Medical Press 2018-10-08 /pmc/articles/PMC6181111/ /pubmed/30323656 http://dx.doi.org/10.2147/JPR.S152216 Text en © 2018 Oswald and Schuster. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Oswald, Jessica C Schuster, Nathaniel M Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
title | Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
title_full | Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
title_fullStr | Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
title_full_unstemmed | Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
title_short | Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
title_sort | lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181111/ https://www.ncbi.nlm.nih.gov/pubmed/30323656 http://dx.doi.org/10.2147/JPR.S152216 |
work_keys_str_mv | AT oswaldjessicac lasmiditanforthetreatmentofacutemigraineareviewandpotentialroleinclinicalpractice AT schusternathanielm lasmiditanforthetreatmentofacutemigraineareviewandpotentialroleinclinicalpractice |